CL2013002623A1 - Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. - Google Patents
Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.Info
- Publication number
- CL2013002623A1 CL2013002623A1 CL2013002623A CL2013002623A CL2013002623A1 CL 2013002623 A1 CL2013002623 A1 CL 2013002623A1 CL 2013002623 A CL2013002623 A CL 2013002623A CL 2013002623 A CL2013002623 A CL 2013002623A CL 2013002623 A1 CL2013002623 A1 CL 2013002623A1
- Authority
- CL
- Chile
- Prior art keywords
- nucleic acid
- molecule
- component
- acid molecule
- bispecific binding
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 210000002966 serum Anatomy 0.000 title 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160921 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002623A1 true CL2013002623A1 (es) | 2014-02-14 |
Family
ID=45895502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002623A CL2013002623A1 (es) | 2011-04-01 | 2013-09-12 | Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. |
Country Status (36)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2865464C (en) * | 2012-03-30 | 2022-07-12 | Boehringer Ingelheim International Gmbh | Ang2-binding molecules |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CA2883807A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| JP2015532273A (ja) * | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ剤を含む薬学的組み合わせ |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| CN107106683B (zh) * | 2015-01-16 | 2021-07-20 | 中央研究院 | 含靶向与效应组件的分子构建体 |
| AR103477A1 (es) | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| ES2973042T3 (es) | 2015-03-31 | 2024-06-18 | Sorriso Pharmaceuticals Inc | Polipéptidos |
| WO2017020001A2 (en) * | 2015-07-29 | 2017-02-02 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
| WO2017030909A1 (en) * | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| IL257565B2 (en) * | 2015-09-23 | 2024-08-01 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| SI3374392T1 (sl) * | 2015-11-13 | 2022-04-29 | Ablynx Nv | Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin |
| WO2017093478A1 (en) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
| US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
| US10919958B2 (en) * | 2016-08-23 | 2021-02-16 | Medimmune Limited | Anti-VEGF-A antibodies and uses thereof |
| WO2018112245A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| RU2648164C1 (ru) * | 2016-12-19 | 2018-03-22 | Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| BR112019022729A2 (pt) | 2017-05-31 | 2020-05-19 | Boehringer Ingelheim Int | polipeptídeos que antagonizam sinalização da wnt em células de tumor |
| WO2018220169A1 (en) * | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2019154776A1 (en) | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| US12171764B2 (en) * | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| CA3105101A1 (en) | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| WO2020089051A1 (en) | 2018-10-29 | 2020-05-07 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| WO2020263312A1 (en) | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
| IL293780A (en) * | 2019-12-11 | 2022-08-01 | Cullinan Man Inc | Anti-serum albumin antibodies |
| WO2021119551A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| WO2021155151A1 (en) * | 2020-01-29 | 2021-08-05 | The Methodist Hospital System | Multivalent ligands targeting cell surface receptors and force measurement platform for making the same |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| AU2021304993B2 (en) | 2020-07-07 | 2024-05-09 | Kanaph Therapeutics Inc. | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
| MX2023009392A (es) * | 2021-02-10 | 2023-11-09 | Shanghai Jemincare Pharmaceuticals Co Ltd | Anticuerpo anti-vegf y uso del mismo. |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| US20240279324A1 (en) | 2021-06-03 | 2024-08-22 | Gensun Biopharma Inc. | Multispecific antagonists |
| CN117500828A (zh) * | 2021-06-04 | 2024-02-02 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| EP4386004A4 (en) * | 2021-08-13 | 2025-08-13 | Innovent Biologics Suzhou Co Ltd | BISPECIFIC ANTI-VEGF A AND ANTI-VEGF C ANTIBODY AND ITS USE |
| CN118251412A (zh) * | 2021-09-10 | 2024-06-25 | 海南康哲维盛科技有限公司 | 抗ang2抗体及其制备方法和应用 |
| CU24770B1 (es) * | 2021-12-15 | 2025-09-01 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN119790077A (zh) | 2022-09-14 | 2025-04-08 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
| CN119866346A (zh) * | 2022-09-14 | 2025-04-22 | 寻济生物科技（北京）有限公司 | 一种抗vegfa抗体或其抗原结合片段及其应用 |
| EP4628512A1 (en) * | 2022-12-01 | 2025-10-08 | Innovent Biologics (Suzhou) Co., Ltd. | Trispecific fusion protein and use thereof |
| EP4628097A1 (en) | 2022-12-01 | 2025-10-08 | Innovent Biologics (Suzhou) Co., Ltd. | Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof |
| WO2024178730A1 (zh) * | 2023-03-02 | 2024-09-06 | 清华大学 | 用于抑制脉络膜新生血管的玻璃体内抗vegf可结晶蛋白药物 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2025219504A1 (en) | 2024-04-19 | 2025-10-23 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US5408535A (en) | 1993-09-07 | 1995-04-18 | Miles Inc. | Video test strip reader and method for evaluating test strips |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2477442A1 (en) | 2002-03-01 | 2003-09-12 | Ball Horticultural Company | Lis promoter for expression of transgenes in floral tissues |
| JP2006515177A (ja) | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置 |
| US20050043220A1 (en) | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| ES2315664T3 (es) | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
| NZ617083A (en) | 2003-08-27 | 2015-04-24 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| DK1687338T3 (da) | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| KR20070086218A (ko) | 2004-12-17 | 2007-08-27 | 제넨테크, 인크. | 자가면역 질환에 대한 이전 요법에 실패했던 환자에서의,자가면역 질환의 항-혈관신생 요법 |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| EP3613767A1 (en) * | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| EP3415535B1 (en) | 2005-05-20 | 2020-12-09 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
| CA2610793A1 (en) | 2005-05-31 | 2007-05-10 | Labnow, Inc. | Methods and compositions related to determination and use of white blood cell counts |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070213266A1 (en) | 2005-09-01 | 2007-09-13 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of Delta-like 4 |
| WO2007043109A1 (ja) | 2005-09-30 | 2007-04-19 | Fujitsu Limited | 情報記憶装置 |
| US20090123474A1 (en) * | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| TW200804593A (en) | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US7570881B2 (en) | 2006-02-21 | 2009-08-04 | Nokia Corporation | Color balanced camera with a flash light unit |
| US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| SG172687A1 (en) | 2006-06-06 | 2011-07-28 | Genentech Inc | Compositions and methods for modulating vascular development |
| JP2009539384A (ja) | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法 |
| RU2429876C2 (ru) | 2006-08-07 | 2011-09-27 | Ридженерон Фармасьютикалз, Инк. | ТЕРАПЕВТИЧЕСКИЕ СПОСОБЫ ЛЕЧЕНИЯ ВАСКУЛЯРНЫХ ЗАБОЛЕВАНИЙ ГЛАЗ АНТАГОНИСТАМИ Dll4 |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2008043821A1 (en) | 2006-10-11 | 2008-04-17 | Ablynx N. V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| US20110076279A1 (en) | 2006-10-20 | 2011-03-31 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN101663319A (zh) | 2007-02-21 | 2010-03-03 | 埃博灵克斯股份有限公司 | 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病 |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| CN101802015B (zh) * | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| JP2011500086A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
| AU2008329221B2 (en) | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| SI2644204T1 (sl) | 2008-03-18 | 2017-08-31 | Genentech, Inc. | Kombinacije konjugata protitelo proti HER2-zdravilo in pertuzumaba |
| EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
| NZ588554A (en) | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| DK2285408T3 (en) | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
| HRP20241467T1 (hr) | 2008-06-25 | 2025-01-03 | Novartis Ag | Stabilna i topljiva protutijela koja inhibiraju vegf |
| CN102143977B (zh) | 2008-09-03 | 2014-08-06 | 霍夫曼-拉罗奇有限公司 | 多特异性抗体 |
| CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8858940B2 (en) | 2008-12-10 | 2014-10-14 | Ablynx N.V. | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| CN102348986B (zh) | 2009-01-13 | 2015-05-06 | Fio公司 | 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备和方法 |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SG177265A1 (en) | 2009-06-17 | 2012-02-28 | Abbott Biotherapeutics Corp | Anti-vegf antibodies and their uses |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110195494A1 (en) | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| US8778340B2 (en) | 2010-02-23 | 2014-07-15 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2012012499A1 (en) | 2010-07-20 | 2012-01-26 | Nurx Pharmaceuticals, Inc. | Optical reader system |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| JP2014500712A (ja) | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| KR20140043351A (ko) | 2011-05-27 | 2014-04-09 | 노파르티스 아게 | 시력 장애의 치료 방법 |
| HRP20230078T1 (hr) | 2011-09-23 | 2023-05-12 | Mereo Biopharma 5, Inc. | Sredstva za vezivanje vegf/dll4 i njihova uporaba |
| CA2865464C (en) * | 2012-03-30 | 2022-07-12 | Boehringer Ingelheim International Gmbh | Ang2-binding molecules |
| US9292583B2 (en) * | 2012-11-27 | 2016-03-22 | Google Inc. | Method of displaying search results |
-
2012
- 2012-03-29 US US13/433,359 patent/US9527925B2/en active Active
- 2012-03-30 MA MA36274A patent/MA34979B1/fr unknown
- 2012-03-30 AP AP2013007085A patent/AP2013007085A0/xx unknown
- 2012-03-30 UY UY0001033998A patent/UY33998A/es unknown
- 2012-03-30 MX MX2016000726A patent/MX343440B/es unknown
- 2012-03-30 ES ES12711201.9T patent/ES2606302T3/es active Active
- 2012-03-30 CN CN201280026064.8A patent/CN103562222B/zh active Active
- 2012-03-30 EP EP12711201.9A patent/EP2694546B1/en active Active
- 2012-03-30 PE PE2013002134A patent/PE20140448A1/es active IP Right Grant
- 2012-03-30 BR BR112013025304-5A patent/BR112013025304B1/pt active IP Right Grant
- 2012-03-30 UA UAA201312685A patent/UA114707C2/uk unknown
- 2012-03-30 DK DK12711201.9T patent/DK2694546T3/en active
- 2012-03-30 MX MX2013010949A patent/MX337543B/es active IP Right Grant
- 2012-03-30 SG SG10201602373TA patent/SG10201602373TA/en unknown
- 2012-03-30 WO PCT/EP2012/055901 patent/WO2012131078A1/en not_active Ceased
- 2012-03-30 HU HUE12711201A patent/HUE030148T2/en unknown
- 2012-03-30 AU AU2012237234A patent/AU2012237234B2/en not_active Ceased
- 2012-03-30 EA EA201600338A patent/EA036746B1/ru not_active IP Right Cessation
- 2012-03-30 JP JP2014501665A patent/JP6023786B2/ja active Active
- 2012-03-30 SG SG2013070842A patent/SG193561A1/en unknown
- 2012-03-30 HR HRP20161689TT patent/HRP20161689T1/hr unknown
- 2012-03-30 KR KR1020137028120A patent/KR101907572B1/ko active Active
- 2012-03-30 SI SI201230813A patent/SI2694546T1/sl unknown
- 2012-03-30 EP EP16189545.3A patent/EP3144322A3/en not_active Withdrawn
- 2012-03-30 RS RS20161083A patent/RS55361B1/sr unknown
- 2012-03-30 CA CA2827817A patent/CA2827817C/en active Active
- 2012-03-30 PT PT127112019T patent/PT2694546T/pt unknown
- 2012-03-30 PH PH1/2013/502044A patent/PH12013502044A1/en unknown
- 2012-03-30 LT LTEP12711201.9T patent/LT2694546T/lt unknown
- 2012-03-30 PL PL12711201T patent/PL2694546T3/pl unknown
- 2012-03-30 AR ARP120101130A patent/AR085984A1/es active IP Right Grant
- 2012-03-30 EA EA201301108A patent/EA025148B1/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013003467A patent/MY171007A/en unknown
- 2012-03-30 CN CN201610173463.7A patent/CN105820243A/zh active Pending
-
2013
- 2013-08-13 IL IL227936A patent/IL227936B/en active IP Right Grant
- 2013-09-12 CL CL2013002623A patent/CL2013002623A1/es unknown
- 2013-09-26 TN TNP2013000390A patent/TN2013000390A1/fr unknown
- 2013-09-27 CO CO13230713A patent/CO6801639A2/es active IP Right Grant
- 2013-10-28 EC ECSP13013001 patent/ECSP13013001A/es unknown
-
2014
- 2014-04-10 HK HK16113827.4A patent/HK1225400A1/zh unknown
-
2016
- 2016-10-07 JP JP2016198857A patent/JP6297657B2/ja active Active
- 2016-11-14 US US15/350,364 patent/US10414828B2/en active Active
- 2016-12-13 CY CY20161101286T patent/CY1118339T1/el unknown
-
2017
- 2017-01-13 AU AU2017200237A patent/AU2017200237B2/en not_active Ceased
-
2019
- 2019-07-18 US US16/515,231 patent/US11161916B2/en active Active
-
2021
- 2021-09-27 US US17/485,561 patent/US20220017642A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002623A1 (es) | Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. | |
| CL2013002622A1 (es) | Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. | |
| CY1125236T1 (el) | Rna τροποποιημενου ακρου | |
| FR23C1013I1 (fr) | Molécules de liaison pour bcma et cd3 | |
| BR112014015111A2 (pt) | composições e processos para anticorpos que se direcionam ao fator p | |
| CL2015001709A1 (es) | Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido. | |
| CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| BR112013005699A2 (pt) | moléculas de ligação a 4-1bb | |
| EA201490768A1 (ru) | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| CL2013001089A1 (es) | Anticuerpos que se une especificamente a tnfalfa humano; composicion farmacéutica que la comprende; molécula de ácido nucleico aislado; vector; metodo para reducir la tendencia a la agregación de un anticuerpo. | |
| DK2723771T3 (da) | Serumalbuminbindende proteiner | |
| BR112013013043A2 (pt) | proteínas de repetição concebidas que se ligam á albumina sérica | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| BR112014000263A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica | |
| CL2016000333A1 (es) | Proteínas de unión a il-1 | |
| CL2015002756A1 (es) | Moléculas fc biespecíficas | |
| BR112015017354A2 (pt) | método para detectar pelo menos uma base modificada | |
| DK2681244T3 (da) | Cea-antistoffer | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2011002380A1 (es) | Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende. | |
| PL2552955T3 (pl) | Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klirens antygenu | |
| BR112013017951A2 (pt) | moléculas de anticorpo que ligam il-17a e il-17f |